Skip Navigation



Japanese Journal of Clinical Oncology Advance Access published online on August 12, 2006
Japanese Journal of Clinical Oncology, doi:10.1093/jjco/hyl083
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
36/10/620    most recent
hyl083v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Demizu, Y.
Right arrow Articles by Sugimura, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Demizu, Y.
Right arrow Articles by Sugimura, K.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 Foundation for Promotion of Cancer Research
Received January 4, 2006
Accepted June 26, 2006

Original Article

Efficacy and Feasibility of Cisplatin-Based Concurrent Chemoradiotherapy for Nasopharyngeal Carcinoma*

Yusuke Demizu 1, Ryohei Sasaki 1 *, Toshinori Soejima 2, Tsutomu Maruta 3, Yoshiaki Okamoto 1, Kazunari Yamada 4, Eisaku Yoden 2, Yasuo Ejima 1, Yosuke Ota 1, Haruhiko Ishida 5, Kenichi Nibu 5, and Kazuro Sugimura 1

1 Division of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan
2 Division of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan; Department of Radiation Oncology, Hyogo Medical Center for Adults, Akashi, Hyogo, Japan
3 Division of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan; Department of Radiology, National Hospital Organization Himeji Medical Center, Himeji, Hyogo, Japan
4 Division of Radiology, Kobe University Graduate School of Medicine, Kobe, Japan; Department of Radiation Oncology, Hyogo Prefectural Tsukaguchi Hospital, Amagasaki, Hyogo, Japan
5 Division of Otorhinolaryngology-Head and Neck Surgery, Kobe University Graduate School of Medicine, Kobe, Japan

* To whom correspondence should be addressed.
Ryohei Sasaki, E-mail: rsasaki{at}med.kobe-u.ac.jp


  Abstract

Objective: To investigate the efficacy and feasibility of a cisplatin-based concurrent chemoradiotherapy (CRT) protocol based on Intergroup Study 0099 for nasopharyngeal carcinoma (NPC).

Methods: Sixteen patients with stage II-IVB NPC were treated with a protocol of cisplatin- based concurrent CRT and adjuvant chemotherapy from 1998 to 2002. Three courses of cisplatin (80 mg/m2) were scheduled during 70 Gy of radiotherapy (RT), and two agents of adjuvant chemotherapy (FP regimen: cisplatin 80 mg/m2 and 5-fluorouracil 800 mg/m2/day by 4-day continuous infusion) were challenged. Overall survival (OS) and relapse-free survival (RFS) rates were calculated by the Kaplan-Meier method.

Results: Median follow-up duration was 45 months. Both 3-year OS and RFS rates were 81%. Proportions of patients who tolerated each scheduled treatment were 94% for RT, 63% for concurrent chemotherapy and 38% for adjuvant chemotherapy.

Conclusions: Our protocol of the cisplatin-based concurrent CRT followed by adjuvant chemotherapy consisting of FP regimen was effective for Japanese patients with NPC. However, the doses and numbers of cycle of chemotherapy need to be modified because of the low compliance rate. Larger numbers of data accumulation and/or multi-institutional trials may be warranted to confirm the efficacy of this protocol.

Keywords: nasopharyngeal carcinoma; radiotherapy; concurrent chemoradiotherapy; cisplatin; Intergroup Study 0099.
*Presented at the 62nd Annual Meeting of Japan Radiological Society, 11-13 April 2003, Yokohama, Japan.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.